phosphodiesterase 4 inhibitors for copdnew york christmas shows 2021

Phosphodiesterase-4 inhibition attenuates pulmonary ... Phosphodiesterase 4 Inhibitors for the Treatment of COPD cAMP exerts an effect beyond the PKA pathway by activating the exchange protein activated by cAMP (EPAC . Phosphodiesterase 4 Inhibitors | DrugBank Online Gross St. Francis Hospital and Medical Center 114 Woodland Street Hartford, CT, 06105-1208, USA Adjunct to bronchodilators for the maintenance treatment of patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations. This activity is intended for physicians. Four groups, containing four monkeys/sex, received vehicle control or rising doses up to 12, 24, or 48 mg/kg of SCH351591 . Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti . CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window Gino Villetti, Chiara Carnini, Loredana Battipaglia, Laurent Preynat, Pier Tonino Bolzoni, IV. Phosphodiesterase 4 (PDE4), a member of the phosphodiesterase enzyme superfamily, specifically inactivates cyclic adenosine monophosphate (cAMP) and is considered to be a molecular target for a new class of drugs for pulmonary diseases. A selective phosphodiesterase 4 inhibitor indicated to decrease the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with a history of exacerbations and chronic bronchitis. O2.2 Phosphodiesterase type-4 inhibitors Phosphodiesterase type-4 (PDE-4) inhibitors act by increasing intracellular concentrations of cyclic adenosine monophosphate (cAMP) to suppress inflammation and bronchoconstriction. The anti-inflammatory effect of two PDE4 inhibitors was investigated in a pre-term rat model . doi: 10.1371/journal.pone.0129327. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Selective inhibitors of this enzyme have been available for a number of years and show a broad spectrum of activity in animal models of COPD and asthma. Therefore, selective PDE4 inhibitors may also provide a therapeutic option for very pre-term infants with bronchopulmonary dysplasia (BPD). Novel anti-inflammatory therapies such as selective phosphodiesterase 4 (PDE4) inhibitors are in clinical development. [Google Scholar] Barr RG, Rowe BH, Camargo CA., Jr Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE(4)) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD. Key words: COPD, phosphodiesterase, inflammation, cancer . Otezla. Objectives. Phosphodiesterase 4 Inhibitors for the Treatment of COPD* Graham Sturton, PhD; and Mary Fitzgerald, PhD Phosphodiesterase 4 (PDE4) is a major cyclic aden-osine-3,5-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth mus-cle, and pulmonary nerves. cAMP produces the functional effect on the protein kinase A (PKA) pathway by phosphorylating the protein causing activation. Apart from smoking cessation, there are no other treatments that slow lung function decline. Selective phosphodiesterase-4 (PDE-4) inhibitors reduce exacerbations, improve dyspnea, and increase lung function in patients with severe COPD. Chronic obstructive pulmonary disease (COPD) is a progressive lung condition caused by damage from harmful chemicals that are breathed in. The invention relates to novel combinations based on anticholinergics, β 2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. Phosphodiesterase-4 (PDE4) inhibitors may offer novel therapeutic strategies in respiratory diseases, including asthma and chronic obstructive pulmonary disease. Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the . Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice PLoS One . The anti-inflammatory effect of two PDE4 inhibitors was investigated in a pre-term rat model . See Prices. Objectives. This is an update of a Cochrane review first published in 2011 and updated in 2013. Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an interesting class of drugs to treat inflammation in COPD. They are FDA approved to manage chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, acute decompensated heart failure, psoriasis, psoriatic arthritis, atopic dermatitis, and neonatal apnea. Roflumilast is one such isoenzyme phosphodiesterase 4 inhibitor that is undergoing Phase III clinical development. Patients typically have symptoms of both chronic bronchitis and emphysema, but the classic triad also includes asthma. 10 PDE4 inhibitors maintain baseline levels of cAMP by interfering with the breakdown of cAMP to adenosine . Vestbo J, Tan L, Atkinson G, et al. Target Audience and Goal Statement. The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic . Their potential role in the management of COPD is described in this review. Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice PLoS One . Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutrophils (PMNs) into the different compartments of the lung, passing an endothelial and epithelial barrier. 64, 65 The main benefit is exacerbation prevention. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Background of the review. Drug class: PDE4 Inhibitors. Corticosteroids and phosphodiesterase 4 (PDE4) inhibitors are anti-inflammatory drugs used for COPD treatment. Basic Pharmacology of Phosphodiesterase-4 (PDE4) Inhibitors. Keywords:Phosphodiesterase, cAMP, inflammation, asthma, COPD Abstract: Type 4 cyclic nucleotide phosphodiesterases (PDE4s) are metallo . Pulm Pharmacol Ther 2010 ;23: 235 - 256 . A Cochrane Review analysed results from RCTs of roflumilast (20 trials, 17,627 patients) and cilomilast (14 trials, 6,457 patients) (Chong 2017) [evidence level I]. The level of connection between phosphodiesterase (PDE)-4 inhibitors and lung cancer will be discussed based on current studies. Drug 24, 1597-1611. doi: 10.1517/13543784.2015.1094054 Phosphodiesterase inhibitors. Therapeutic Class • Overview/Summary: Daliresp® (roflumilast) is a first in class oral phosphodiesterase (PDE) 4 inhibitor that is Food and Drug Administration (FDA)-approved to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor that has been approved for use in the United States and several other countries in the last few years for chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and frequent exacerbations. Chronic obstructive pulmonary disease (COPD) is estimated to affect 32 million persons in the United States and is the fourth leading cause of death in this country. Other oral medications such as phosphodiesterase-4 inhibitors (PDE4Is) can be added for treating a subgroup of COPD, based on specific criteria. Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for treating chronic inflammatory diseases. Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3′,5′-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves. The goal of this activity is to emphasize the enormity of the problem that chronic obstructive pulmonary disease (COPD) poses, to talk about some of the current treatments, and to highlight the potential role that phosphodiesterase (PDE) 4 inhibitors may play in the future. Phosphodiesterases (PDEs) are a superfamily of enzymes that inactivate the intracellular second messengers cAMP and cGMP. Hesperetin, a selective phosphodiesterase (PDE)4 inhibitor, is present in the traditional Chinese medicine, "Chen Pi." Therefore, we were interested in investigating its effects on ovalbumin- (OVA-) induced airway hyperresponsiveness, and clarifying its rationale for ameliorating asthma and chronic obstructive pulmonary disease (COPD). Dosing. Wittmann M, Helliwell PS. Title: Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD VOLUME: 13 ISSUE: 27 Author(s):Zheng Huang and Joseph A. Mancini Affiliation:Dept of Biochemistry and Molecular Biology, Merck Frosst, PO Box 1005, Pointe Claire/Dorval H9R4P8. We have previously reported that GPD-1116, an inhibitor of phosphodiesterase (PDE) 4, exhibits anti-inflammatory effects in a model of cigarette smoke-induced emphysema in senescence-accelerated P1 mice. 2003; 327:643-8. PDE-4 is a family of enzymes that catalyze the degradation of adenosine 3monophosphate and cyclic guanosine ′,5′- monophosphate to their corresponding 5′-nucleotide mono- Phosphodiesterase-4 (PDE₄) inhibitors are a relatively new class of medicines marketed to improve COPD. PDE4B and PDE4D subtypes play a pivotal role in inflammation, whereas blocking PDE4D is suspected to . A selective inhibitor the phosphodiesterase type 4 (PDE4), which is used as maintenance therapy of severe chronic obstructive pulmonary disease with a forced expiratory volume at one second < 50% of predicted in a background of chronic bronchitis. Phosphodiesterase-4 inhibitors (called PDE4 inhibitors) and methylxanthines are two types of medication that may be used to treat people with chronic obstructive pulmonary disease (COPD). Recent studies showed evidence that phosphodiesterase (PDE)4-inhibitors stabilized endothelial cells. This can make them too narrow for enough air to pass in and out of the lungs. In people with chronic obstructive pulmonary disease (COPD), what are the benefits and risks of phosphodiesterase 4 inhibitors? Phosphodiesterase-4 enzyme (PDE-4) inhibitors are medications used to treat chronic obstructive pulmonary disease ().COPD is a progressive condition with chronic inflammation that damages the lungs and causes breathing difficulties.. Phosphodiesterase-4 enzyme inhibitors are a novel class of drugs and the first non-steroidal anti-inflammatory drug used in the treatment of COPD. This review focuses on clinical data on PDE4 , of the compound UK-500,001 . Do not use this medicine to treat sudden breathing problems. 50,51 It is a nonselective phosphodiesterase inhibitor with several potentially important actions including bronchodilation, enhancement of skeletal muscle contractility, and it is a CNS stimulant. Daliresp (roflumilast) is an oral selective phosphodiesterase (PDE)-4 inhibitor that is Food and Drug Administration (FDA)-approved to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. A letter to the editor was published in the European Journal of Internal Medicine, detailing a retrospective observational analysis of a database of patients on roflumilast for COPD. A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP). Selective inhibitors of this enzyme have been available for a number of Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD) Prog Drug Res. Keywords: COPD, phosphodiesterase, inflammation, cancer. Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3′,5′-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves. Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators" Exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the natural history of COPD and contribute to quality-of-life impairment (1), hospital admissions (2), and disease progression (3). Roflumilast, a selective PDE4 inhibitor, has been extensively studied for the efficacy . Chronic obstructive pulmonary disease (COPD) is estimated to affect 32 million persons in the United States and is the third leading cause of death in this country. Its clinical effects have been extensively reviewed elsewhere. Selective PDE-4 . Introduction: Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells. Roflumilast is a selective phosphodiesterase-4 inhibitor, used in the treatment of COPD in patients with chronic bronchitis and frequent exacerbations. Our current understanding of the pathophysiology of chronic obstructive pulmonary disease (COPD) and its management Keywords: Chronic obstructive pulmonary disease, Inflammation, Phosphodiesterase 4, Roflumilast Correspondence to: Nicholas J. By mouth. Among these, the most widely used are four types of phosphodiesterase inhibitors: phosphodiesterase type 5 inhibitors (PDE5 inhibitor), phosphodiesterase type 4 inhibitors (PDE4 inhibitor), phosphodiesterase type 3 inhibitors (PDE3 inhibitor), and nonspecific . A comment will be made whether lung cancer is induced to patients receiving phosphodiesterase (PDE)-4 inhibitors from the drug or former smoking habit. The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Indications and dose. We studied the effect of corticosteroid combined with PDE4 inhibitors on cytokine release form circulating and pulmonary CD8 cells, and on . in asthma and COPD have been developed. Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer John Organtzis , 1 Sofia Lampaki , 1 Paul Zarogoulidis , 1, Haidong Huang , 2 Qiang Li , 2 Antonis Papaiwannou , 1 Konstantinos Syrigos , 3 Konstantinos Porpodis , 1 Theodora Tsiouda , 4 Wolfgang Hohenforst-Schmidt , 5 Georgia Trakada , 6 Robert Fred Henry Walter , 7, 8 . Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. 2015 Jun 9;10(6):e0129327. A comment will be made whether lung cancer is induced to patients receiving phosphodiesterase (PDE)-4 inhibitors from the drug or former smoking habit. Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD). Roflumilast, a]' phosphodiesterase-4 (PDE 4 ) inhibitor, has been reported to significantly reduce moderate to severe exacerbations by 17% compared to placebo for severe COPD patients with chronic . Patients typically have symptoms of chronic bronchitis and emphysema, but the classic triad also includes asthma (see the image below). Daliresp (roflumilast) is a type of oral medication used to treat chronic obstructive pulmonary disease (COPD) and other lung diseases. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE 4) inhibitors proposed to reduce the airway inflammation . Pulm Pharmacol Ther 2010 ;23: 235 - 256 . Daliresp. This study evaluated the efficacy, safety and tolerability of the novel inhaled phosphodiesterase-4 inhibitor CHF6001 added-on to formoterol in patients with chronic obstructive pulmonary disease (COPD). doi: 10.1371/journal.pone.0129327. This medicine is used to prevent COPD flare-ups. It is an Roflumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties. The present authors report the findings of a phase II trial of a novel inhaled PDE4 inhibitor. The level of connection between phosphodiesterase (PDE)-4 inhibitors and lung cancer will be discussed based on current studies. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Roflumilast (Daliresp) Roflumilast is a selective . Phosphodiesterase-4 (PDE4) inhibitors may offer novel therapeutic strategies in respiratory diseases, including asthma and chronic obstructive pulmonary disease. Inhaled PDE4 inhibitors aim to restrict systemic drug exposure to enhance the potential for clinical benefits (in the lungs) versus adverse events (systemically). nary vasculature. Three doses, 0.1, 0.4 and 1.0 mg b.i.d. Selective phosphodiesterase 4 (PDE4) inhibitor is a promising class of drugs that has been studied for the treatment of COPD. Selective phosphodiesterase-4 inhibitors increase cyclic adenosine-3′,5′-monophosphate (cAMP) levels, resulting in a broad spectrum of anti-inflammatory effects in almost all inflammatory cells. They have both bronchodilator and anti-inflammatory effects. Bronchodilators and steroids will be the medications your doctor is most likely to recommend first when it comes to COPD treatment. III. The 11 known enzymes in this family have different tissue distribution and substrate specificities. Modulation of systemic and airway inflammation is their pivotal mechanism of action. Expert Opin. To evaluate the efficacy and safety of oral PDE 4 inhibitors in the management of stable COPD. Brit Med J. Crossref , Medline , Google Scholar Selective PDE4 inhibitor is different from xanthine in terms of mechanisms and pharmacokinetic profiles. Phosphodiesterase-4 Inhibitors: New Insights into Mechanisms of Action and Safety Issues. APREMILAST is used to treat plaque psoriasis, psoriatic arthritis, and certain oral ulcers. Roflumilast 500 mcg orally daily ($250/month) It is part of a category of drugs called phosphodiesterase-4 inhibitors (PDE4 inhibitor), which work to suppress inflammation in the airways of people who are resistant to standard COPD treatments. Two currently available medicines - roflumilast and cilomilast - are taken as a tablet. Selective phosphodiesterase-4 inhibitors are used in the treatment of severe Chronic Obstructive Pulmonary Disease ( COPD) to reduce the risk of . Phosphodiesterase (PDE) 4 Inhibitors . The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Phosphodiesterase type 4 inhibitor (PDE4 inhibitor) Roflumilast; Severe COPD; PDE4 inhibition → ↑ cAMP in bronchial epithelium, granulocytes, and neutrophils; Inhibition of proinflammatory mediators; Deceleration of fibrotic changes in the lung; Relaxation of the bronchial musculature; Phosphodiesterase type 3 inhibitor (PDE3 inhibitor . Piclamilast. At present, the only phosphodiesterase inhibitor available for COPD treatment is roflumilast, an orally administered PDE4 inhibitor. 50,51 Phosphodiesterase hydrolyzes the 3′-phosphodiester bond in . Isoenzyme phosphodiesterase 4 inhibitors are novel therapeutic agents in late clinical development for the treatment of chronic obst ructive pulmonary disease and asthma, both diseases with significant unmet treatment needs. Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide [1,2]. Its beneficial clinical effects occur preferentially in . It is a member of the larger family of PDE inhibitors.The PDE4 family of enzymes are the most prevalent PDE in immune cells.They are predominantly responsible for hydrolyzing cAMP within both immune . CD8 lymphocytes play an important role in the pathogenesis of COPD. KEYWORDS: Anti-inflammatory, chronic obstructive pulmonary disease, cilomilast, cyclic Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE 4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD. Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3',5'-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves. Little is known of the combined effect of these drugs on COPD CD8 cells. Therefore, selective PDE4 inhibitors may also provide a therapeutic option for very pre-term infants with bronchopulmonary dysplasia (BPD). Background: Chronic obstructive pulmonary disease (COPD) affects symptoms, lung function, quality of life and life expectancy. The fact that phosphodiesterase 4 inhibitors have potent anti-inflammatory effects and are administered orally, thereby reaching the systemic circulation, may decrease the severity of systemic comorbidities in chronic obstructive pulmonary disease patients. 2015 Jun 9;10(6):e0129327. Selective inhibitors of . Mechanism. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE 4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD. Roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide) is an oral PDE4 inhibitor for the treatment of COPD (Boswell-Smith et al., 2006b). Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on phosphodiesterase enzymes. Roflumilast was identified in 1993 from a series of benzamides in a comprehensive screening programme ( Amschler, 1995 ). cAMP is a key secondary messenger for intracellular signaling processes (Francis and Corbin, 1999). 1999; 53:193-229. Selective phosphodiesterase-4 (PDE-4) inhibitors reduce exacerbations, improve dyspnea, and increase lung function in patients with severe COPD. Phosphodiesterase-4 inhibition in COPD. Phosphodiesterase-4 Inhibitor increases lung, intracellular cAMP. the long-term decline in lung function characteristic of COPD (GOLD 2018). Inhaled medications are currently standard for COPD treatment. ROFLUMILAST decreases inflammation in the lungs. Eligible patients had symptomatic COPD, post-bronchodilator forced expiratory volume in 1 s (FEV1) 30-70% . Am J Respir Crit Care Med 2007; 176: 162-66. There are 11 families of phosphodiesterase enzymes and PDE inhibitors for each. Recent findings Some of the . Selective inhibitors of this enzyme have been available for a number of years and show a broad spectrum of activity in animal models of COPD and asthma. Drug class: PDE4 Inhibitors. Severe, refractory COPD with frequent exacerbations. Theophylline has been used since the 1930s for the treatment of asthma and COPD. People with COPD have airways that are irritated and inflamed. Phosphodiesterase (PDE) 4 inhibitors prevent the metabolism of cyclic adenosine monophosphate, thereby reducing inflammation. This is an update of a Cochrane review first published in 2011 and updated in 2013. Clinical Data on Dual PDE3/4 Inhibitors in Patients with COPD. chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. SCH351591, a novel phosphodiesterase-4 inhibitor under investigation as a potential therapeutic for asthma and chronic obstructive pulmonary disease (COPD), was evaluated in a 3-month rising-dose study in Cynomolgus monkeys. To evaluate the efficacy and safety of oral PDE 4 inhibitors in the management of stable COPD. . Furthermore, PDE inhibitors modulate cough reflex and inhibit airway mucus secretion. tent and selective phosphodiesterase-4 (PDE-4) inhibitor for the treatment of chronic obstructive pulmonary dis-ease (COPD), was investigated using the C-QTc approach. Roflumilast (Daliresp) Roflumilast is a selective . "We do not yet know whether the effects over a longer period of time may translate into attenuation of the accelerated rate of decline of lung function that characterizes patients with COPD and leads to . Indications. So far, anti-inflammatory medications (eg, inhaled corticosteroids) have failed to show a major effect on the decline of lung function in COPD patients. "Phosphodiesterase-4 inhibitors represent a promising new class of substances for use in anti-inflammatory treatment of [COPD]," they conclude. The fact that phosphodiesterase 4 inhibitors have potent anti-inflammatory effects and are administered orally, thereby reaching the systemic circulation, may decrease the severity of systemic comorbidities in chronic obstructive pulmonary disease patients. Phosphodiesterase-4 (PDE-4) inhibitors. In the present study, we further characterized the pharmacological profile of GPD-1116 in several experiments in vitro and in vivo.
Winning Ways For Your Mathematical Plays, Lauterborn 1990 Reference, Men's Legacy Sateen Jacketmen's Legacy Sateen Jacket, Vitamin C Before Or After Snail Mucin, Malawi Vs Namibia Prediction, Olympic Tennis Women's Singles Winners 2021, Birkenstock Split Suede,